© 2025 Supernus Pharmaceuticals, Inc. All Rights Reserved. Safe Harbor Statement This presentation and other matters discussed today or answers that may be given to questions asked include forward-looking statements within the meaning of the federal securities laws. These statements, among other things, relate to Supernus' business strategy, goals and expectations concerning its product candidates, ability to integrate the acquired portfolio into its infrastructure, future operations, prospects, plans and o ...

Supernus Pharmaceuticals (SUPN) M&A Announcement June 16, 2025 08:30 AM ET Speaker0 Good morning, everyone, and welcome to Sperna's Business Update Conference Call. At this time, all participants are in a listen only mode. Later, we will conduct a question and answer session. Instructions will follow at that time. As a reminder, this conference call is being recorded. I would now like to turn the conference over to Peter Bassa, Investor Relations representative for Abertis Pharmaceuticals. You may begin. Sp ...

Supernus Pharmaceuticals (SUPN) 2025 Conference June 04, 2025 02:00 PM ET Speaker0 Session. I'm Andrew Tsai, senior biotech analyst at Jefferies. Thanks for joining today. It's my pleasure to have Jack Qatar next to me, CEO of Supernus. Welcome, Jack. Speaker1 Thank you. Thanks for having us. Speaker0 As usual, those who may be less familiar with the Supernus story, any opening remarks you'd like to make about your story, what you're working on and key priorities over the next year? Speaker1 Yes, sure. Good ...

New video series explores the impact of ADHD on relationships and the role of Qelbree in helping Jay’s ADHD symptom managementROCKVILLE, Md., May 29, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals is expanding its partnership with TV personality and sports reporter Jay Glazer in a new content series featuring his wife, Rosie Glazer. The series, which launches its first episode on the All About ADHD YouTube channel in May for Mental Health Awareness Month, offers an intimate look at how ADHD impacts relat ...

ROCKVILLE, Md., May 28, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company received Paragraph IV Notice Letters from third parties notifying Supernus that the third parties submitted Abbreviated New Drug Applications (ANDAs) for viloxazine extended-release capsules, eq. 100, 150, and 200 mg base. Supernus is currently ...

ROCKVILLE, Md., May 28, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack A. Khattar, President and CEO of Supernus Pharmaceuticals, will participate in a fireside chat at the 2025 Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 2:00 p.m. ET in New York City. Investors interested in arranging a meeting ...

ROCKVILLE, Md., May 20, 2025 (GLOBE NEWSWIRE) -- Actress, author, podcaster, and mom, Busy Philipps, is stepping into an important new role as 'Ms. Represented' in partnership with Supernus Pharmaceuticals for a new campaign aimed at empowering women with attention-deficit/hyperactivity disorder (ADHD) to understand their symptoms. The campaign, which launched during Mental Health Awareness Month (May) on Bustle – a leading online destination for women's news – draws on Busy's personal journey navigating he ...

期权市场动态 - Supernus Pharmaceuticals的2025年6月20日到期、行权价30美元的看涨期权隐含波动率位居所有股票期权前列 [1] - 高隐含波动率表明投资者预期公司股价将出现大幅波动 可能由即将发生的事件驱动 [2] 公司基本面 - 公司属于医疗-仿制药行业 在Zacks行业排名中处于后16%位置 [3] - 过去60天内 一位分析师上调了当季每股收益预期 从46美分升至48美分 无分析师下调预期 [3] 分析师观点 - 期权交易者可能利用高隐含波动率进行卖出期权策略 以获取时间价值衰减收益 [4] - 当前Zacks评级为3级(持有) 显示分析师对其中性看法 [3] 行业表现 - 医疗-仿制药行业整体表现疲弱 在Zacks行业排名中处于底部区间 [3]

财务表现 - 公司2025年第一季度营收1.498亿美元，同比增长4.3%，超出Zacks共识预期2.91% [1] - 每股收益0.42美元，去年同期为0.00美元，超出分析师预期10.53% [1] - 净产品销售额1.4199亿美元，同比增长2.6%，略高于分析师平均预期 [4] - 特许权收入784万美元，同比增长51.2%，显著高于分析师平均预期580万美元 [4] 产品线表现 - Trokendi XR销售额1280万美元，同比下降20%，但高于分析师平均预期858万美元 [4] - Oxtellar XR销售额1020万美元，同比下降62.1%，低于分析师平均预期1229万美元 [4] - Qelbree销售额6470万美元，同比增长43.5%，接近分析师平均预期6554万美元 [4] - GOCOVRI销售额3070万美元，同比增长15.9%，略高于分析师平均预期3013万美元 [4] - APOKYN销售额1500万美元，同比下降10.2%，低于分析师平均预期1670万美元 [4] 市场反应 - 公司股价过去一个月上涨0.4%，同期标普500指数上涨11.5% [3] - 公司目前Zacks评级为2级（买入），显示其可能在未来跑赢大盘 [3] 分析师关注点 - 投资者关注营收和盈利的同比变化及与华尔街预期的对比 [2] - 关键指标对预测股价表现有重要影响，需对比历史数据和分析师预期 [2]

Supernus Pharmaceuticals (SUPN) Q1 2025 Earnings Call May 06, 2025 04:30 PM ET Company Participants Peter Vozzo - Managing DirectorJack Khattar - CEO, President & DirectorTimothy Dec - Senior VP & CFOJack Padovano - Equity Research Associate - BioPharma Conference Call Participants None - AnalystStacy Ku - AnalystDavid Amsellem - Sr. Research Analyst Operator Good afternoon, and welcome to Supernus Pharmaceuticals First Quarter twenty twenty five Financial Results Conference Call. At this time, all particip ...